| Target Price | ¥14,994.00 |
| Price | ¥12,905.00 |
| Potential |
16.19%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Organo 2026 .
The average Organo target price is ¥14,994.00.
This is
16.19%
register free of charge
¥16,800.00
30.18%
register free of charge
¥13,736.00
6.44%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Organo to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Organo stock has an average upside potential 2026 of
16.19%
register free of charge
|
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 163.27 | 179.38 |
| 8.59% | 9.87% | |
| EBITDA Margin | 20.24% | 22.49% |
| 23.94% | 11.12% | |
| Net Margin | 14.79% | 15.77% |
| 28.48% | 6.61% |
5 Analysts have issued a sales forecast Organo 2026 . The average Organo sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Organo EBITDA forecast 2026. The average Organo EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Organo Analysts have issued a net profit forecast 2026. The average Organo net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 525.36 | 615.10 |
| 39.38% | 17.08% | |
| P/E | 20.91 | |
| EV/Sales | 3.32 |
5 Analysts have issued a Organo forecast for earnings per share. The average Organo EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


